Natixis Bleichroeder downgrades Medicis (MRX) to Hold from Buy, noting the firm will  likely...

|By:, SA News Editor

Natixis Bleichroeder downgrades Medicis (MRX) to Hold from Buy, noting the firm will  likely start losing money if it loses Solodyn to generics, and may not win the race to gets Solodyn "2.0" approved. N.B. lowers target to $12, but sees downside risk to $7. Shares -3.1% premarket.